Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04644237 · OUTCOME

Overall Survival Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer Tumors

Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) · Source last updated 2025-11-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
9 months after the last participant is randomized or later to data cut off, up to approximately 35 months

What was measured

Overall survival (OS) is defined as the time from date of randomization until death from any cause.

Analysis population: Full Analysis Set

Groups in this outcome

Trastuzumab Deruxtecan 5.4 mg/kg

Participants randomized to receive trastuzumab deruxtecan 5.4 mg/kg, administered by intravenous infusion every 3 weeks (Q3W).

Trastuzumab Deruxtecan 6.4 mg/kg

Participants randomized to receive trastuzumab deruxtecan 6.4 mg/kg, administered by intravenous infusion every 3 weeks (Q3W).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Trastuzumab Deruxtecan 5.4 mg/kg102
Trastuzumab Deruxtecan 6.4 mg/kg50

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Trastuzumab Deruxtecan 5.4 mg/kg19.0Not reported14.7NANot estimable due to insufficient number of participants with events
Trastuzumab Deruxtecan 6.4 mg/kg17.9Not reported13.8NANot estimable due to insufficient number of participants with events
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        Not estimable due to insufficient number of participants with events
        group Id
        OG000
        lower Limit
        14.7
        upper Limit
        NA
        value
        19.0
      2. comment
        Not estimable due to insufficient number of participants with events
        group Id
        OG001
        lower Limit
        13.8
        upper Limit
        NA
        value
        17.9
denoms
  1. counts
    1. group Id
      OG000
      value
      102
    2. group Id
      OG001
      value
      50
    units
    Participants
description
Overall survival (OS) is defined as the time from date of randomization until death from any cause.
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants randomized to receive trastuzumab deruxtecan 5.4 mg/kg, administered by intravenous infusion every 3 weeks (Q3W).
    id
    OG000
    title
    Trastuzumab Deruxtecan 5.4 mg/kg
  2. description
    Participants randomized to receive trastuzumab deruxtecan 6.4 mg/kg, administered by intravenous infusion every 3 weeks (Q3W).
    id
    OG001
    title
    Trastuzumab Deruxtecan 6.4 mg/kg
param Type
MEDIAN
population Description
Full Analysis Set
reporting Status
POSTED
time Frame
9 months after the last participant is randomized or later to data cut off, up to approximately 35 months
title
Overall Survival Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer Tumors
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice